A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

NCT05788536 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Interventions

GENETIC: DB-OTO
GENETIC: DB-OTO

Sponsor

Regeneron Pharmaceuticals